These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Prevalence of BRAF and NRAS mutations in fast-growing melanomas. Nagore E; Hacker E; Martorell-Calatayud A; Traves V; Guillen C; Hayward NK; Whiteman D Pigment Cell Melanoma Res; 2013 May; 26(3):429-31. PubMed ID: 23448684 [No Abstract] [Full Text] [Related]
11. BRAF and NRAS Mutations are Not Mutually Exclusive in Melanoma and in Single Melanoma Cells. Uguen A; Guéguen P; Talagas M; Costa S; De Braekeleer M; Marcorelles P Appl Immunohistochem Mol Morphol; 2016 Mar; 24(3):e14-5. PubMed ID: 26317309 [No Abstract] [Full Text] [Related]
12. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands. van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725 [TBL] [Abstract][Full Text] [Related]
13. BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study. Frank GA; Aleksakhina SN; Zavalishina LE; Kekeyeva TV; Venina AR; Ivantsov AO; Mitiushkina NV; Moiseyenko AV; Pfeifer W; Strelkova TN; Imyanitov EN Melanoma Res; 2016 Oct; 26(5):442-7. PubMed ID: 27433783 [No Abstract] [Full Text] [Related]
14. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas. Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760 [TBL] [Abstract][Full Text] [Related]
15. KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases. Zebary A; Jangard M; Omholt K; Ragnarsson-Olding B; Hansson J Br J Cancer; 2013 Aug; 109(3):559-64. PubMed ID: 23860532 [TBL] [Abstract][Full Text] [Related]
16. Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: a GenoMEL study. Zebary A; Omholt K; van Doorn R; Ghiorzo P; Harbst K; Hertzman Johansson C; Höiom V; Jönsson G; Pjanova D; Puig S; Scarra GB; Harland M; Olsson H; Egyhazi Brage S; Palmer J; Kanter-Lewensohn L; Vassilaki I; Hayward NK; Newton-Bishop J; Gruis NA; Hansson J; J Invest Dermatol; 2014 Jan; 134(1):287-290. PubMed ID: 23771122 [No Abstract] [Full Text] [Related]
17. KIT, NRAS, and BRAF mutations in nail apparatus melanoma. Dika E; Altimari A; Patrizi A; Gruppioni E; Fiorentino M; Piraccini BM; Misciali C; Barisani A; Fanti PA Pigment Cell Melanoma Res; 2013 Sep; 26(5):758-60. PubMed ID: 23782496 [No Abstract] [Full Text] [Related]
18. Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas. Manca A; Lissia A; Capone M; Ascierto PA; Botti G; Caracò C; Stanganelli I; Colombino M; Sini M; Cossu A; Palmieri G J Transl Med; 2015 Jan; 13():37. PubMed ID: 25627962 [TBL] [Abstract][Full Text] [Related]
19. [ Spectrum of oncogene mutations is different in melanoma subtypes]. Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785 [TBL] [Abstract][Full Text] [Related]
20. A Murine Model for Metastatic Conjunctival Melanoma. de Waard NE; Cao J; McGuire SP; Kolovou PE; Jordanova ES; Ksander BR; Jager MJ Invest Ophthalmol Vis Sci; 2015 Apr; 56(4):2325-33. PubMed ID: 25722211 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]